| Literature DB >> 20559487 |
Patrícia Mendonça Pauletti1, Lucas Silva Cintra, Caio Guedes Braguine, Ademar Alves da Silva Filho, Márcio Luís Andrade E Silva, Wilson Roberto Cunha, Ana Helena Januário.
Abstract
This review discusses the isolation, structural elucidation, and biological activities of halogenated indole alkaloids obtained from marine invertebrates. Meridianins and related compounds (variolins, psammopemmins, and aplicyanins), as well as aplysinopsins and leptoclinidamines, are focused on. A compilation of the (13)C-NMR spectral data of these selected natural indole alkaloids is also provided.Entities:
Keywords: 13C-NMR spectral data; bioactivity; halogenated indole alkaloids; marine invertebrates; structure elucidation
Mesh:
Substances:
Year: 2010 PMID: 20559487 PMCID: PMC2885079 DOI: 10.3390/md8051526
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of plakohypaphorines A, B, and C (1–3).
Figure 2Structures of meridianins 4–10.
Effects of meridianins A–G (4–10) on the activity of protein kinases (IC50 in μM).
| Protein kinase | Meridianins | ||||||
|---|---|---|---|---|---|---|---|
| A | B | C | D | E | F | G | |
| CDK1/cyclin B | 2.50 | 1.50 | 3.00 | 13.00 | 0.18 | 20.00 | 150.00 |
| CDK5/p25 | 3.00 | 1.00 | 6.00 | 5.50 | 0.15 | 20.00 | 140.00 |
| PKA | 11.00 | 0.21 | 0.70 | 1.00 | 0.09 | 3.20 | 120.00 |
| PKG | 200.0 | 1.00 | 0.40 | 0.80 | 0.60 | 0.60 | 400.00 |
| GSK-3β | 1.30 | 0.50 | 2.00 | 2.50 | 2.50 | 2.00 | 350.00 |
| CK1 | nt | 1.00 | 30.00 | 100.00 | 0.40 | nt | nt |
nt: not tested.
Figure 3Structures of variolins 11–15.
Figure 4Structures of meriolins 16–29.
Effects of variolin B (12) and meriolins 1(16), 10 (25), and 11 (26) on the activity of protein kinases (IC50 in μM).
| Protein kinase | Variolin B | Meriolin 1 | Meriolin 10 | Meriolin 11 |
|---|---|---|---|---|
| CDK1/cyclin B | 0.06 | 0.78 | 0.24 | 2.20 |
| CDK2/cyclin A | 0.08 | 0.09 | 0.06 | 1.3 |
| CDK5/p25 | 0.09 | 0.51 | 0.23 | 0.68 |
| CDK9/cyclin T | 0.026 | 0.026 | 0.05 | 1.00 |
| GSK-3α/β | 0.07 | 0.63 | 2.00 | 30.0 |
| CK1 | 0.005 | 0.2 | 3.0 | 1.3 |
| DYRK1A | 0.08 | 0.13 | 0.13 | 0.3 |
Figure 5Structures of psammopemmins 30–32 and aplycianins 33–38.
Cytotoxicity (GI50 values reported in μM) and antimitotic activity (IC50, mM) of aplicyanins B (34), D (36), E (37), F (38) and (±) aplicyanin A, B, and E.
| Compound | Cell lines | Antimitotic Activity | ||
|---|---|---|---|---|
| A-549 | HT-29 | MDA-MB-231 | ||
| Aplicyanin B | 0.66 | 0.39 | 0.42 | 1.19 |
| Aplicyanin D | 0.63 | 0.33 | 0.41 | 1.09 |
| Aplicyanin E | 8.70 | 7.96 | 7.96 | nt |
| Aplicyanin F | 1.31 | 0.47 | 0.81 | 0.18 0.036 |
| (±)-aplicyanin A | 0.27 | 0.11 | 0.27 | nt |
| (±)-aplicyanin B | 0.51 | 0.33 | 0.98 | nt |
| (±)-aplicyanin E | na | na | 10.9 | nt |
na: not active;
nt: not tested.
Figure 6Structures of aplysinopsins 39–53.
Figure 7Structures of leptoclinidamines 54–56.
Figure 8Structures of chartelline, chartellamide, securamines and securines 57–68.
13C chemical shifts (δ in ppm) of meridianins, psammopemmins, and aplicyanins halogenated derivatives.
| Carbon | 5 | 6 | 7 | 8 | 9 | 10 | 30 | 32 | 33 | 34 | 35 | 36 | 37 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solvent | A | A | A | A | B | B | A | A | B | B | B | B | B |
| Ref. | |||||||||||||
| 2 | 129.9 | 129.6 | 129.2 | 129.2 | 131.6 | 129.1 | 128.3 | 128.8 | 125.3 | 125.6 | 123.8 | 124.1 | 124.7 |
| 3 | 113.7 | 113.3 | 114.8 | 116.1 | 114.9 | 115.4 | 113.7 | 113.6 | 113.6 | 113.8 | 112.0 | 111.2 | 112.3 |
| 3a | 114.0 | 127.1 | 124.5 | 115.2 | 127.6 | 126.8 | 114.3 | 113.9 | 124.1 | 127.8 | 124.3 | 124.1 | 123.5 |
| 4 | 153.0 | 124.6 | 124.3 | 152.0 | 127.7 | 122.7 | 152.0 | 152.9 | 121.9 | 121.8 | 122.5 | 122.4 | 124.6 |
| 5 | 108.8 | 113.4 | 123.1 | 107.3 | 118.4 | 123.4 | 105.4 | 108.4 | 115.2 | 114.3 | 114.4 | 114.6 | 119.3 |
| 6 | 116.7 | 124.7 | 113.9 | 126.7 | 117.1 | 121.9 | 124.3 | 116.4 | 125.9 | 126.1 | 126.9 | 127.1 | 116.4 |
| 7 | 105.3 | 113.9 | 114.5 | 92.6 | 117.5 | 112.8 | 102.3 | 105.0 | 114.5 | 114.6 | 111.4 | 111.5 | 114.6 |
| 7a | 139.7 | 135.9 | 138.0 | 136.9 | 138.5 | 138.9 | 139.2 | 139.5 | 137.2 | 137.2 | 132.7 | 132.7 | 133.6 |
| 2′ | 160.7 | 163.6 | 163.6 | 160.2 | 165.3 | 165.6 | 161.7 | 161.6 | 155.7 | 152.3 | 155.7 | 152.4 | 155.7 |
| 4′ | 160.8 | 162.3 | 162.3 | 161.8 | 163.9 | 165.6 | 160.7 | 159.7 | 48.1 | 48.2 | 47.6 | 47.7 | 47.4 |
| 5′ | 104.6 | 105.4 | 105.4 | 104.8 | 107.1 | 107.6 | 158.3 | 158.8 | 28.3 | 26.9 | 28.3 | 26.6 | 28.3 |
| 6′ | 157.1 | 157.2 | 157.2 | 159.0 | 156.2 | 157.5 | 104.3 | 104.3 | 38.6 | 38.6 | 38.4 | 38.2 | 38.3 |
| CH3CO | 173.9 | 174.0 | |||||||||||
| CH3CO | 24.1 | 24.1 | |||||||||||
| OCH3 | 66.8 | 66.7 | 67.0 |
13C chemical shifts (δ in ppm) for halogenated aplicyanin 38 and aplysinopsins derivatives.
| Carbon | 38 | 39 | 40 (Z) | 40 (E) | 41 | 43 (Z) | 43 (E) | 44 ( | 44 ( | 50 (E) | 51 (Z) | 51 (E) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solvent | B | A | A | A | A | A | A | A | A | A | A | A |
| Ref. | ||||||||||||
| 2 | 125.0 | 127.4 | 129.6 | 129.0 | 127.7 | 129.9 | 129.0 | 130.6 | 132.6 | 129.3 | 127.5 | 130.1 |
| 3 | 111.5 | 108.4 | 111.9 | 110.7 | 108.7 | 112.0 | 110.8 | 108.3 | 108.2 | 108.7 | 108.7 | 108.9 |
| 3a | 123.2 | 127.8 | 125.7 | 126.7 | 126.9 | 125.7 | 126.8 | 127.8 | 128.4 | 127.5 | 126.3 | 127.3 |
| 4 | 124.5 | 118.1 | 121.0 | 119.9 | 119.6 | 121.1 | 120.0 | 123.6 | 122.5 | 120.2 | 120.1 | 119.2 |
| 5 | 119.5 | 119.5 | 122.4 | 122.5 | 121.8 | 122.4 | 122.5 | 116.9 | 116.9 | 122.6 | 122.9 | 122.8 |
| 6 | 116.6 | 121.8 | 114.5 | 114.4 | 121.8 | 114.5 | 114.5 | 115.2 | 115.2 | 114.0 | 115.0 | 114.6 |
| 7 | 114.6 | 111.8 | 114.3 | 114.4 | 114.0 | 114.3 | 114.4 | 116.8 | 117.2 | 114.6 | 114.4 | 115.0 |
| 7a | 133.6 | 135.7 | 136.7 | 136.5 | 136.2 | 136.5 | 136.5 | 135.8 | 135.8 | 136.5 | 136.6 | 136.5 |
| 8 | 102.8 | 106.1 | 113.3 | 101.5 | 106.5 | 113.9 | 108.9 | 115.1 | 107.5 | 101.0 | 106.5 | |
| 1′ | 126.5 | 136.9 | 134.9 | 126.9 | 136.9 | 136.6 | 135.7 | 135.7 | 125.1 | 124.9 | 125.4 | |
| 2′ | 152.3 | |||||||||||
| 3′ | 26.8 | 150.8 | 157.7 | 155.0 | 162.1 | 157.1 | 154.7 | 155.9 | 152.7 | 152.8 | 155.4 | 153.4 |
| 4′ | 47.6 | |||||||||||
| 5′ | 26.8 | 162.3 | 169.0 | 167.0 | 150.4 | 169.0 | 167.1 | 163.2 | 160.8 | 162.0 | 167.3 | 163.9 |
| 6′ | 38.1 | |||||||||||
| 2′-NCH3 | 27.0 | 24.4 | 27.8 | 27.8 | 24.3 | |||||||
| 4′- NCH3 | 24.9 | 25.6 | 25.6 | 26.6 | 25.5 | 25.4 | 26.0 | 26.0 | 26.3 | |||
| OCH3 | 67.1 | |||||||||||
| CH3CO | 174.0 | |||||||||||
| CH3CO | 24.1 |
13C chemical shifts (δ in ppm) for halogenated aplysinopsins and leptoclinidamines derivatives.
| Carbon | 46 | 47 | 48 | 49 | 53 | 56 | Carbon | 46 | 47 | 48 | 49 | 53 | 56 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solvent | B | B | B | B | ni | A | 4′ | 119.7 | |||||
| Ref. | |||||||||||||
| 2 | 124.8 | 125.1 | 125.4 | 125.4 | 123.3 | 129.0 | 5′ | 171.8 | 171.9 | 169.7 | 170.0 | 124.8 | |
| 3 | 106.5 | 105.3 | 104.6 | 104.7 | 115.0 | 109.4 | 6′ | 117.3 | |||||
| 3a | 125.7 | 125.6 | 125.6 | 125.6 | 126.4 | 124.9 | 7′ | 115.9 | |||||
| 4 | 119.3 | 119.3 | 119.4 | 119.0 | 120.1 | 122.9 | 7a′ | 137.4 | |||||
| 5 | 121.9 | 122.0 | 122.1 | 122.0 | 121.5 | 123.4 | 8′ | 44.5 | |||||
| 6 | 114.7 | 114.8 | 114.9 | 114.9 | 125.9 | 114.6 | 9′ | 72.3 | |||||
| 7 | 113.9 | 114.0 | 114.0 | 114.0 | 113.0 | 114.8 | 11′ | 159.0 | |||||
| 7a | 137.2 | 137.1 | 137.2 | 137.2 | 139.5 | 137.0 | 13′ | 172.5 | |||||
| 8 | 29.4 | 30.1 | 30.1 | 30.4 | 27.6 | 164.1 | 2′-NCH3 | 24.7 | 25.3 | 25.6 | 25.6 | ||
| 9 | 72.3 | 4′- NCH3 | 24.1 | 24.6 | 24.7 | 24.6 | |||||||
| 10 | 50.0 | 10-NCH3 | 33.1 | ||||||||||
| 11 | 161.6 | 25.7 | 12-NCH3 | 26.6 | |||||||||
| 12 | 136.4 | 13-SCH3 | 18.6 | ||||||||||
| 13 | 174.0 | 125.9 | 14-NCH3 | 33.5 | |||||||||
| 15 | 138.1 | 16-NCH3 | 34.2 | ||||||||||
| 17 | 172.2 | 10′-NCH3 | 28.4 | ||||||||||
| 1′ | 64.0 | 89.0 | 94.3 | 93.8 | 12′-NCH3 | 26.5 | |||||||
| 2′ | 125.6 | OCH3 | 52.3 | ||||||||||
| 3′ | 158.1 | 156.6 | 157.2 | 157.0 | 104.4 | OCH2 | 61.5 | ||||||
| 3′a | 127.7 | CH3 | 13.7 |
ni: not informed.
13C chemical shifts (δ in ppm) for halogenated chartelline, chartellamides, securamines and securines derivatives.
| Carbon | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Solvent | C | C | C | C | C | C | C | C | A | A | C |
| Ref. | |||||||||||
| 2 | 120.4 | 120.6 | 127.4 | 127.1 | 135.9 | 136.1 | 136.4 | 135.9 | 130.2 | 130.3 | 48.3 |
| 3 | 109.5 | 108.1 | 95.1 | 95.3 | 101.6 | 101.2 | 101.2 | 101.5 | 100.9 | 103.6 | 96.3 |
| 4 | 130.5 | 130.8 | 115.8 | 116.0 | 187.5 | 188.0 | 187.3 | 187.2 | 121.1 | 121.5 | 140.7 |
| 6 | 133.2 | 116.6 | 122.5 | 121.1 | 166.6 | 166.7 | 166.4 | 166.0 | 125.0 | 127.6 | 156.8 |
| 8 | 126.6 | 129.5 | 145.5 | 144.8 | 85.6 | 85.7 | 85.4 | 84.7 | 135.6 | 135.3 | 80.7 |
| 9 | 65.9 | 65.2 | 41.6 | 41.9 | 44.0 | 43.9 | 44.2 | 43.7 | 40.6 | 40.8 | 39.2 |
| 10 | 41.6 | 41.6 | 64.9 | 64.6 | 59.4 | 59.5 | 58.7 | 52.1 | 71.2 | 70.9 | 61.4 |
| 11 | 45.9 | 46.8 | 48.6 | 48.3 | 41.8 | 41.7 | 41.9 | 42.8 | 30.8 | 30.8 | 41.0 |
| 12 | 67.9 | 70.5 | 87.4 | 87.4 | 89.2 | 89.1 | 88.0 | 89.8 | 132.7 | 133.9 | 87.9 |
| 14 | 141.5 | 141.1 | 147.0 | 148.0 | 147.0 | 145.7 | 148.0 | 146.9 | 134.4 | 134.5 | 147.5 |
| 15 | 117.6 | 117.6 | 109.3 | 112.2 | 114.7 | 111.1 | 113.5 | 114.7 | 110.9 | 113.2 | 114.6 |
| 16 | 125.9 | 126.0 | 129.0 | 122.3 | 123.1 | 129.4 | 120.6 | 123.0 | 120.5 | 114.1 | 122.3 |
| 17 | 132.5 | 132.5 | 119.9 | 122.5 | 124.9 | 121.9 | 128.0 | 124.9 | 118.1 | 119.4 | 123.5 |
| 18 | 119.4 | 119.4 | 123.9 | 125.0 | 125.6 | 124.6 | 123.8 | 125.5 | 117.5 | 121.1 | 125.2 |
| 19 | 124.8 | 124.7 | 127.8 | 126.7 | 128.0 | 128.8 | 126.3 | 127.9 | 128.5 | 126.0 | 130.4 |
| 20 | 67.4 | 67.6 | 50.0 | 49.4 | 45.0 | 45.3 | 46.8 | 44.9 | 105.7 | 106.3 | 45.6 |
| 21 | 47.8 | 48.0 | 34.1 | 33.8 | 34.2 | 34.4 | 32.6 | 34.2 | 30.7 | 30.6 | 33.8 |
| 22 | 162.5 | 162.1 | 172.8 | 172.2 | 170.3 | 170.5 | 170.0 | 170.0 | 169.4 | 169.1 | 171.2 |
| 23 | 164.9 | 164.1 | 19.0 | 18.9 | 17.2 | 17.3 | 17.1 | 18.6 | 19.8 | 19.8 | 15.4 |
| 24 | 15.4 | 17.1 | 31.9 | 31.8 | 21.1 | 21.1 | 21.1 | 22.6 | 28.7 | 28.7 | 21.1 |
Comparison of the biological activity of the main natural halogenated indole alkaloids meridianins, psammopemmins, aplicyanins, and aplysinopsins.
| Compound | Biological Activity |
|---|---|
| Meridianin B ( | Inhibition of protein kinases; Cytotoxicity [ |
| Meridianin C ( | Inhibition of protein kinases; Cytotoxicity [ |
| Meridianin D ( | Inhibition of protein kinases; Cytotoxicity [ |
| Meridianin E ( | Inhibition of protein kinases; Cytotoxicity [ |
| Meridianin F ( | Inhibition of protein kinases [ |
| Psammopemmin B ( | nt |
| Psammopemmin C ( | nt |
| Aplicyanin A ( | na |
| Aplicyanin B ( | Cytotoxicity and antimitotic activity [ |
| Aplicyanin C ( | na |
| Aplicyanin D ( | Cytotoxicity and antimitotic activity [ |
| Aplicyanin E ( | Cytotoxicity [ |
| Aplicyanin F ( | Cytotoxicity and antimitotic activity [ |
| 6-bromo-2′-de-N-methylaplysinopsin ( | Antimalarial [ |
| Inhibitor of nitric oxide synthase (nNOS) [ | |
| 6-bromoaplysinopsin ( | Antimalarial [ |
| Allelochemical [ | |
| 6-bromo-4′-de- | nt |
| 6-bromo-4′-demethyl-3′- | nt |
| 5,6-dibromo-2′-demethylaplysinopsin ( | Inhibitor of nitric oxide synthase (nNOS) [ |
| 6-bromo-1′,8-dihydro-aplysinopsin ( | Antimicrobial [ |
| 6-bromo-1′-hydroxy-1′,8-dihydroaplysinopsin ( | Antimicrobial [ |
| 6-bromo-1′-methoxy-1′,8-dihydroxyaplysinopsin ( | Antimicrobial [ |
| 6-bromo-1′-ethoxy-1′,8-dihydroxyaplysinopsin ( | Antimicrobial [ |
| 6-bromo-3′-deimino-3′-oxoaplysinopsin ( | nt |
| 6-bromo-3′-deimino-2′,4′-bis(demethyl)-3′-Oxoaplysinopsin ( | nt |
| Dimer of 6-bromo-2′-de- | Antimicrobial [ |
| Tubastrindole A ( | - |
nt: not tested.
na: not active.